Here's an interesting commentary from Seeking Alpha's Jason Chew on the development of ADC market. The post notes that both Seattle Genetics (SGN-35) and Genentech/Immunogen with T-DM1 are having successful results with antibody drug conjugates in late stage clinicals with Hodgkin's disease and breast cancer respectively. As noted here in a post last week, the industry is watching these two drugs wend their way toward approval with great interest. If these are successful in the clinic, and make it through the regulatory maze, it is expected that many companies on the sidelines will move more aggressively into ADC programs of their own - particularly in the oncology area.
When this happens, Jason argues that Seattle Genetics and Immunogen will be sitting pretty with their core technologies to enable the development of new ADC molecules. Both companies have invested in creating and improving linker technology and high potency payloads. Companies entering the area will need to choose to license for existing players or to develop their own IP. Having a positive regulatory history and exisiting technology ready to go should favor a licensing pathway in most cases to capitalize on speed to clinic (and market).
SeaGen and Immunogen are both positioned to take advantage of this perceived influx into the area and to draw a paralell to the electronics/computer industry - may become the next "Intel inside" companies in oncology. They won't make the primary antibody perhaps but will enable the creation of ADCs with their linkers and HP-APIs.
Posted by Bruce Lehr October 2nd 2010.